Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX)’s share price rose 1.1% during mid-day trading on Monday . The stock traded as high as C$26.13 and last traded at C$25.39. Approximately 5,137,967 shares traded hands during trading, an increase of 229% from the average daily volume of 1,560,571 shares. The stock had previously closed at C$25.11.
VRX has been the topic of several research analyst reports. TD Securities upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price objective on the stock in a research note on Wednesday, November 8th. Royal Bank of Canada restated a “sector perform” rating and set a C$23.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Wednesday, November 8th.
In related news, Director Schutter Richard Urbain De bought 10,000 shares of the business’s stock in a transaction on Friday, November 17th. The shares were bought at an average cost of C$14.33 per share, for a total transaction of C$143,300.00.
COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International (VRX) Stock Price Up 1.1%” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/12/18/valeant-pharmaceuticals-international-vrx-trading-up-1-1.html.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.